Answers are grounded in this paper and cite their sources.
In this first real-world study of a national sample of elderly US patients treated with ibrutinib, we found a clear unmet need for improved management of ibrutinib-related AEs and/or new treatments to improve real-world outcomes in patients with CLL.
No takes yet. Share an insight, caveat, or question.
Huntington et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: